Advertisement
Table 2 Demographic, serological, clinical data and medication prior to induction therapy
| Demographic, serological, clinical data and medication | MMF | CYC |
|---|---|---|
| (number = 23) | (number = 24) | |
| SLEDAI-2 k (points); median (range) | 12 (6 to 20) | 14 (2 to 30) |
| gender female number (%) | 15 (65.2) | 16 (66.7) |
| age (years); mean ± SD | 35 ± 10 | 34 ± 10 |
| duration (years); median (range) | 4 (1 to 24) | 3 (0 to 25) |
| age at initial diagnosis of SLE (years); mean ± SD | 29 ± 10 | 30 ± 10 |
| medication | ||
| prednisone (mg/day); median (range) | 10.0 (5.0-30.0) | 10.0 (0.0-250.0) |
| co-medication with antimalarials number (%) | 15 (65.2) | 11 (45.8) |
| preceding immunosuppressive medication number (%) | ||
| - CYC | 11 (47.8) | |
| - MMF | 6 (25.0) | |
| - AZA | 8 (24.8) | 7 (29.2) |
| - MTX | 2 (8.7) | 2 (8.3) |
| - CsA | 1 (4.3) | 1 (4.2) |
| - none | 1 (4.3)a | 8 (33.3)a |
| manifestations number (%) | ||
| class III-V nephritis flare | 17 (73.9) | 18 (75.0) |
| eGFR <60 ml/min | 4 (18.2) | 6 (25.0) |
| C3c <0.9 g/L | 14 (60.9)b | 23 (95.8)b |
| neuropsychiatric | 1 (4.3) | 3 (12.5) |
| mucocutaneous/cutaneous | 14 (60.9) | 14 (58.3) |
| arthritis | 8 (34.8) | 6 (25.0) |
| serositis | 2 (8.7) | 5 (20.8) |
| myositis | 2 (8.7) | 3 (12.5) |
| autoantibodies number (%) | ||
| anti-dsDNA >7 U/ml | 21 (91.3) | 21 (87.5) |
| anti-Ro >7 U/ml | 15 (65.2) | 13 (54.2) |
| anti-La >7 U/ml | 5 (21.7) | 5 (20.8) |
| anti-U1-RNP >5 U/ml | 11 (47.8) | 13 (54.2) |
| anti-SM >5 U/ml | 8 (34.8) | 11 (45.8) |
